Pythagoras Trial (US Clinical trial)
Results of one, three, and five year follow-up.

All-cause mortality	7.9%	21.9%	32.5%	6.0%	13.4%	26.9%
	[12/151]	[33/151]	[49/151]	[4/67]	[9/67]	[18/67]
Shrinkage of aneurysm	43.0%	55.8%	60.0%	39.2%	60.5%	64.0%
(>5mm)	[49/114]	[48/86]	[36/60]	[20/51]	[26/43]	[16/25]
Expansion of aneurysm	1.8%	7.0%	15.0%	0.0%	7.0%	4.0%
(>5mm)	[2/114]	[6/86]	[9/60]	[0/51]	[3/43]	[1/25]
Type I/III endoleaks	1.9%	0.0%	0.0%	0.0%	0.0%	0.0%
	[2/103]	[0/76]	[0/47]	[0/46]	[0/38]	[0/25]
Migration of stent graft	1.8%	5.8%	3.3%	0.0%	2.4%	4.0%
exceeding 10mm	[2/114]	[5/86]	[2/60]	[0/51]	[1/42]	[1/25]

Aorfix™

(N=151)

3 year | 5year

Neck angle ≥60°

Aorfix™

(N=67)

Neck angle < 60°

1year

Medical institutions took part in: 45
Principal Investigator: Mark Fillinger, MD (Dartmouth-Hitchcock Medical Center)
References: Malas MB; Hicks CW; Jordan WD Jr; Hodgson KJ; Mills JL Sr;
Makaroun MS; Belkin M; Fillinger MF. Five-year outcomes of the
PYTHAGORAS U.S. clinical trial of the Aorfix endograft for endovascular
aneurysm repair in patients with highly angulated aortic necks. Journal
of Vascular Surgery. 2017, 65(6), 1598-1607.